Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T2DM Susceptibility Gene Expression
NCT06277466Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Detection of T2DM susceptibility gene expression in newly diagnosed T2DM patients, Detection of T2DM susceptibility gene expression in controls and 1 more. Started Jan 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06277466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277466.